Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.

Carmen AlcaláF GascónFrancisco Pérez-MirallesJ A DomínguezS Gil-PerotínB Casanova

Published in: Journal of neurology (2019)

Treating RRMS patients with alemtuzumab or rituximab after fingolimod withdrawal is effective and safe, without significant differences between both groups in our series.

Keyphrases

multiple sclerosis
diffuse large b cell lymphoma
white matter
chronic lymphocytic leukemia
hodgkin lymphoma
smoking cessation
disease activity